S&P 500   5,135.96 (-0.26%)
DOW   38,824.00 (+0.09%)
QQQ   433.80 (-0.84%)
AAPL   173.32 (-0.23%)
MSFT   415.76 (-0.37%)
META   483.39 (-2.73%)
GOOGL   146.62 (-0.72%)
AMZN   174.04 (-0.25%)
TSLA   172.00 (-1.04%)
NVDA   859.06 (-2.88%)
NIO   5.38 (-2.89%)
AMD   181.97 (-4.55%)
BABA   73.37 (-0.20%)
T   17.28 (-0.12%)
F   12.25 (+0.57%)
MU   92.16 (-1.73%)
CGC   3.45 (-7.01%)
GE   169.71 (-0.12%)
DIS   113.74 (-0.10%)
AMC   4.35 (-0.91%)
PFE   27.69 (-0.11%)
PYPL   63.62 (-0.95%)
XOM   113.06 (+0.68%)
S&P 500   5,135.96 (-0.26%)
DOW   38,824.00 (+0.09%)
QQQ   433.80 (-0.84%)
AAPL   173.32 (-0.23%)
MSFT   415.76 (-0.37%)
META   483.39 (-2.73%)
GOOGL   146.62 (-0.72%)
AMZN   174.04 (-0.25%)
TSLA   172.00 (-1.04%)
NVDA   859.06 (-2.88%)
NIO   5.38 (-2.89%)
AMD   181.97 (-4.55%)
BABA   73.37 (-0.20%)
T   17.28 (-0.12%)
F   12.25 (+0.57%)
MU   92.16 (-1.73%)
CGC   3.45 (-7.01%)
GE   169.71 (-0.12%)
DIS   113.74 (-0.10%)
AMC   4.35 (-0.91%)
PFE   27.69 (-0.11%)
PYPL   63.62 (-0.95%)
XOM   113.06 (+0.68%)
S&P 500   5,135.96 (-0.26%)
DOW   38,824.00 (+0.09%)
QQQ   433.80 (-0.84%)
AAPL   173.32 (-0.23%)
MSFT   415.76 (-0.37%)
META   483.39 (-2.73%)
GOOGL   146.62 (-0.72%)
AMZN   174.04 (-0.25%)
TSLA   172.00 (-1.04%)
NVDA   859.06 (-2.88%)
NIO   5.38 (-2.89%)
AMD   181.97 (-4.55%)
BABA   73.37 (-0.20%)
T   17.28 (-0.12%)
F   12.25 (+0.57%)
MU   92.16 (-1.73%)
CGC   3.45 (-7.01%)
GE   169.71 (-0.12%)
DIS   113.74 (-0.10%)
AMC   4.35 (-0.91%)
PFE   27.69 (-0.11%)
PYPL   63.62 (-0.95%)
XOM   113.06 (+0.68%)
S&P 500   5,135.96 (-0.26%)
DOW   38,824.00 (+0.09%)
QQQ   433.80 (-0.84%)
AAPL   173.32 (-0.23%)
MSFT   415.76 (-0.37%)
META   483.39 (-2.73%)
GOOGL   146.62 (-0.72%)
AMZN   174.04 (-0.25%)
TSLA   172.00 (-1.04%)
NVDA   859.06 (-2.88%)
NIO   5.38 (-2.89%)
AMD   181.97 (-4.55%)
BABA   73.37 (-0.20%)
T   17.28 (-0.12%)
F   12.25 (+0.57%)
MU   92.16 (-1.73%)
CGC   3.45 (-7.01%)
GE   169.71 (-0.12%)
DIS   113.74 (-0.10%)
AMC   4.35 (-0.91%)
PFE   27.69 (-0.11%)
PYPL   63.62 (-0.95%)
XOM   113.06 (+0.68%)
NASDAQ:VVOS

Vivos Therapeutics (VVOS) Stock Price, News & Analysis

$4.32
-0.15 (-3.36%)
(As of 09:30 AM ET)
Today's Range
$4.32
$4.32
50-Day Range
$4.26
$9.45
52-Week Range
$2.73
$48.79
Volume
4,004 shs
Average Volume
123,181 shs
Market Capitalization
$5.75 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
VVOS stock logo

About Vivos Therapeutics Stock (NASDAQ:VVOS)

Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was founded in 2016 and is based in Littleton, Colorado.

VVOS Stock Price History

VVOS Stock News Headlines

They said crypto was dead. It went up 100X.
Bitcoin’s haters are out again. Despite the price doubling in the last six months alone… That hasn’t stopped the experts from piling on. Warren Buffett’s right-hand man Charlie Munger called crypto investors “idiots” in one of his last interviews. JPMorgan CEO Jamie Dimon, recently called Bitcoin a “pet rock” and “a hyped-up fraud.” But when it comes to cryptos, these are exactly the people you shouldn’t listen to. They’ve predicted crypto’s demise for years.
They said crypto was dead. It went up 100X.
Bitcoin’s haters are out again. Despite the price doubling in the last six months alone… That hasn’t stopped the experts from piling on. Warren Buffett’s right-hand man Charlie Munger called crypto investors “idiots” in one of his last interviews. JPMorgan CEO Jamie Dimon, recently called Bitcoin a “pet rock” and “a hyped-up fraud.” But when it comes to cryptos, these are exactly the people you shouldn’t listen to. They’ve predicted crypto’s demise for years.
Vivos Therapeutics announces women-led airway health event
Why Is Vivos Therapeutics (VVOS) Stock Down 35% Today?
Why Is Vivos Therapeutics (VVOS) Stock Up 290% Today?
See More Headlines
Receive VVOS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vivos Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/15/2021
Today
3/19/2024
Next Earnings (Estimated)
4/04/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:VVOS
Fax
N/A
Employees
154
Year Founded
N/A

Profitability

Net Income
$-23,840,000.00
Net Margins
-106.28%
Pretax Margin
-106.27%

Debt

Sales & Book Value

Annual Sales
$16.02 million
Book Value
$4.80 per share

Miscellaneous

Free Float
1,204,000
Market Cap
$5.95 million
Optionable
Optionable
Beta
8.04
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives


VVOS Stock Analysis - Frequently Asked Questions

How have VVOS shares performed in 2024?

Vivos Therapeutics' stock was trading at $12.44 at the start of the year. Since then, VVOS shares have decreased by 64.1% and is now trading at $4.47.
View the best growth stocks for 2024 here
.

Are investors shorting Vivos Therapeutics?

Vivos Therapeutics saw a drop in short interest in February. As of February 29th, there was short interest totaling 23,600 shares, a drop of 19.2% from the February 14th total of 29,200 shares. Based on an average trading volume of 187,600 shares, the short-interest ratio is presently 0.1 days. Currently, 2.1% of the company's shares are short sold.
View Vivos Therapeutics' Short Interest
.

When is Vivos Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024.
View our VVOS earnings forecast
.

How were Vivos Therapeutics' earnings last quarter?

Vivos Therapeutics, Inc. (NASDAQ:VVOS) announced its quarterly earnings results on Monday, November, 15th. The company reported ($6.50) EPS for the quarter, missing the consensus estimate of ($4.00) by $2.50. The business had revenue of $4.55 million for the quarter, compared to analyst estimates of $4.50 million. Vivos Therapeutics had a negative net margin of 106.28% and a negative trailing twelve-month return on equity of 508.27%.

When did Vivos Therapeutics' stock split?

Vivos Therapeutics shares reverse split before market open on Friday, October 27th 2023. The 1-25 reverse split was announced on Friday, October 27th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, October 27th 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

When did Vivos Therapeutics IPO?

(VVOS) raised $20 million in an initial public offering on Friday, December 11th 2020. The company issued 3,300,000 shares at a price of $5.00-$7.00 per share. Roth Capital Partners served as the underwriter for the IPO and Craig-Hallum Capital Group and National Securities Corporation were co-managers.

Who are Vivos Therapeutics' major shareholders?

Vivos Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Strategic Wealth Investment Group LLC (9.68%), Armistice Capital LLC (4.29%), Vanguard Group Inc. (0.80%), Vanguard Group Inc. (0.79%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Bradford K Amman and Ronald Kirk Huntsman.
View institutional ownership trends
.

How do I buy shares of Vivos Therapeutics?

Shares of VVOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VVOS) was last updated on 3/19/2024 by MarketBeat.com Staff

From Our Partners